51. Therapeutic Characteristics, Chemotherapy-Related Toxicities and Survivorship in Colorectal Cancer Patients
- Author
-
Abdelouahed Er-Raki, Bouchra Meddah, Rachid Razine, Meriem Slaoui, Yahia Cherrah, and Zineb Aoullay
- Subjects
0301 basic medicine ,Oncology ,Male ,medicine.medical_specialty ,Drug-Related Side Effects and Adverse Reactions ,Colorectal cancer ,medicine.medical_treatment ,Rectum ,chemotherapy toxicities ,Antineoplastic Agents ,Disease ,Survivorship ,03 medical and health sciences ,0302 clinical medicine ,Cancer Survivors ,Internal medicine ,Survivorship curve ,Epidemiology ,medicine ,Humans ,Adverse effect ,Aged ,Retrospective Studies ,Chemotherapy ,business.industry ,General Medicine ,overall survival (OS) ,Middle Aged ,medicine.disease ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Toxicity ,Original Article ,Female ,business ,Colorectal Neoplasms - Abstract
BACKGROUND: Colorectal Cancer (CRC) is a major health problem around the globe. In Morocco, the disease ranks third after breast and lung cancers. This study is the first in Morocco to investigate epidemiological, clinical and therapeutic features while exhaustively describing toxic side-effects to chemotherapy of CRC and studying the 3-years survivorship.METHODS: This is a descriptive and analytical retrospective study of about 290 patients with CRC enrolled during the period of January-December 2013. Statistical analysis was performed to correlate clinicopathological data with chemotherapy toxicity and survivorship in patients, by Chi2 test. Overall Survival (OS) rate has been calculated by the Kaplan-Meier method and compared using Log-rank test.RESULTS: Fifty-five percent had a tumor localized in rectum, and 42,8% in colon. Mean age of these patients at diagnosis was 56,16 ±14,6. incidence rate of adverse events (grade I to IV) was 85,6%. Diarrhea was the predominant toxicity (4.6%) occurring at a high grade (grade III-IV). The 3-years OS rate of patients with CRC was 71%. OS decreased by age, and patients with age subgroup between 40 to 59 years had a better OS than the other age subgroups (60 to 79 years and >80 years) with a p-value of 0.0001. Occurence of toxicity (all grades and types) was linked to a higher survival rates compared to the group who had no toxicity noticed (p-value of 0.001).CONCLUSION: Our study shows that patients who had a polychemotherapy had a better OS than those who had monotherapy (p-value of 0.002).
- Published
- 2020